title: Clinical efficacy and safety of biapenem for febrile neutropenia in patients with underlying hematopoietic diseases: a multi-institutional study.
abstract: A multi-institutional study was conducted to assess efficacy and safety of biapenem (BIPM), a carbapenem antibiotic, as an initial-stage therapeutic agent for febrile neutropenia (FN) in patients with hematopoietic diseases. A total of 216 patients from 25 medical institutions were enrolled in this study; of these, 204 were included in the safety analysis and 178 in the efficacy analysis. The combined (excellent and good) response rate was 67.9%, and antipyretic effect (subsidence + tendency to subsidence) was achieved within 3 and 5 days of treatment in 67.3 and 75.9% of patients, respectively. Thus, the clinical responses were gratifying. A response rate of 61.7% (37/60) was observed even in high-risk FN patients in whom neutrophil counts prior to and at 72 h after the start of BIPM were ≤100/μl. BIPM is considered to be a highly promising drug, with prompt onset of clinical benefit, as an initial-stage therapeutic agent for the treatment of FN in patients with hematopoietic diseases.
authors.affiliation: Department of Oncology and Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. y-nak@white.plala.or.jp
authors.forename: Yasunori
authors.initials: Y
authors.lastname: Nakagawa
authors.forename: Kenshi
authors.initials: K
authors.lastname: Suzuki
authors.forename: Takayuki
authors.initials: T
authors.lastname: Hirose
authors.forename: Takaaki
authors.initials: T
authors.lastname: Chou
authors.forename: Shin
authors.initials: S
authors.lastname: Fujisawa
authors.forename: Michiko
authors.initials: M
authors.lastname: Kida
authors.forename: Kensuke
authors.initials: K
authors.lastname: Usuki
authors.forename: Yoji
authors.initials: Y
authors.lastname: Ishida
authors.forename: Shuichi
authors.initials: S
authors.lastname: Taniguchi
authors.forename: Yasuji
authors.initials: Y
authors.lastname: Kouzai
authors.forename: Shigeru
authors.initials: S
authors.lastname: Tomoyasu
authors.forename: Koji
authors.initials: K
authors.lastname: Miyazaki
authors.forename: Masaaki
authors.initials: M
authors.lastname: Higashihara
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Ando
authors.forename: Sadao
authors.initials: S
authors.lastname: Aoki
authors.forename: Ayako
authors.initials: A
authors.lastname: Arai
authors.forename: Nobu
authors.initials: N
authors.lastname: Akiyama
authors.forename: Kiyohiko
authors.initials: K
authors.lastname: Hatake
authors.forename: Shinichiro
authors.initials: S
authors.lastname: Okamoto
authors.forename: Kazuo
authors.initials: K
authors.lastname: Dan
authors.forename: Kazuma
authors.initials: K
authors.lastname: Ohyashiki
authors.forename: Akio
authors.initials: A
authors.lastname: Urabe
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000890:Anti-Infective Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001419:Bacteria / Q000187:drug effects; D005260:Female; D005334:Fever / Q000097:blood / Q000188:drug therapy*; D019337:Hematologic Neoplasms / Q000097:blood / Q000150:complications*; D006801:Humans; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D009503:Neutropenia / Q000150:complications / Q000188:drug therapy*; D009504:Neutrophils; D013845:Thienamycins / Q000008:administration & dosage* / Q000009:adverse effects; D016896:Treatment Outcome
chemical_list: D000890:Anti-Infective Agents; D013845:Thienamycins; C065257:biapenem